Avid Bioservices Inc (CDMO)

[Carboat]

(PS) signaling pathway is a very interesting target

and I'm convinced he is referring to Bavituximab

So to Dr. Wolchock it is "interesting" and someone MAY be referring to BAVI. These are not exactly ringing endorsements, or scientists excited about a new drug. If BAVI is such a given to be a key component in the future of oncology, why only such ambivalent statements to report? Shouldn't it be Time "Man of the Year" or something big?